David C Huang

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3880605/david-c-huang-publications-by-year.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

230 papers	32,438 citations	86 h-index	179 g-index
241 ext. papers	35,750 ext. citations	11.6 avg, IF	6.69 L-index

#	Paper	IF	Citations
230	The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL.. *Cell Death and Disease*, **2022**, 13, 291	9.8	1
229	Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. *Genome Biology*, **2021**, 22, 310	18.3	10
228	Mesenchymal stromal cell apoptosis is required for their therapeutic function. *Nature Communications*, **2021**, 12, 6495	17.4	11
227	The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. *Leukemia*, **2021**, 35, 2114-2118	10.7	8
226	Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X and BCL-2. *Journal of Medicinal Chemistry*, **2021**, 64, 5447-5469	8.3	3
225	PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. *Genome Medicine*, **2021**, 13, 58	14.4	9
224	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. *Blood*, **2021**, 137, 2721-2735	2.2	14
223	TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancer. *Cell Death and Differentiation*, **2021**, 28, 3316-3328	12.7	6
222	BCL2 and MCL1 inhibitors for hematologic malignancies. *Blood*, **2021**, 138, 1120-1136	2.2	7
221	Transcriptional silencing of fetal hemoglobin expression by NonO. *Nucleic Acids Research*, **2021**, 49, 9711-9723	19.2	1
220	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. *Blood Advances*, **2021**, 5, 4054-4058	7.8	9
219	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. *Nature Communications*, **2021**, 12, 5337	17.4	1
218	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. *Blood Advances*, **2020**, 4, 2762-2767	7.8	14
217	Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells. *Cell Death and Differentiation*, **2020**, 27, 2531-2533	12.7	3
216	MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex. *Cell Death and Differentiation*, **2020**, 27, 2484-2499	12.7	16
215	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. *Cell Death and Differentiation*, **2020**, 27, 2217-2233	12.7	18
214	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 7-8	2.2	5

213	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 9-10	2.2	2
212	BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic. *Cancers*, **2020**, 12,	6.6	5
211	Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. *Cell Death and Disease* , **2020**, 11, 735	9.8	6
210	Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the Pathway. *ACS Chemical Biology*, **2020**, 15, 2702-2713	4.9	11
209	EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins. *Cell Death and Differentiation*, **2020**, 27, 1554-1568	12.7	12
208	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. *Blood*, **2020**, 135, 791-803	2.2	176
207	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. *Blood*, **2020**, 135, 773-777	2.2	55
206	Replication stress induces mitotic death through parallel pathways regulated by WAPL and telomere deprotection. *Nature Communications*, **2019**, 10, 4224	17.4	13
205	A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis. *Nature Chemical Biology*, **2019**, 15, 1057-1066	11.7	16
204	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. *British Journal of Haematology*, **2019**, 186, e188-e191	4.5	24
203	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. *Nature Communications*, **2019**, 10, 2385	17.4	84
202	Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax. *Blood*, **2019**, 134, 171-171	2.2	2
201	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. *Blood*, **2019**, 134, 170-170	2.2	12
200	Venetoclax for the treatment of mantle cell lymphoma. *Annals of Lymphoma*, **2019**, 3, 4-4	1.8	0
199	Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. *Blood Advances*, **2019**, 3, 4202-4214	7.8	35
198	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. *Leukemia*, **2019**, 33, 905-917	10.7	84
197	Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. *Nature Medicine*, **2019**, 25, 119-129	50.5	94
196	Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes. *Cell Death and Differentiation*, **2019**, 26, 1516-1530	12.7	8

195	KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. *Journal of Controlled Release*, **2019**, 296, 40-53	11.7	21
194	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. *Cancer Discovery*, **2019**, 9, 342-353	24.4	188
193	BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock to Reprogramming. *Stem Cell Reports*, **2018**, 10, 331-338	8	9
192	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. *Leukemia*, **2018**, 32, 303-312	10.7	96
191	The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1 Activation. *Cell Reports*, **2018**, 25, 2339-2353.e4	10.6	102
190	VDAC2 enables BAX to mediate apoptosis and limit tumor development. *Nature Communications*, **2018**, 9, 4976	17.4	73
189	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. *Cancer Discovery*, **2018**, 8, 1582-1597	24.4	194
188	CARM1-mediated methylation of protein arginine methyltransferase 5 represses human globin gene expression in erythroleukemia cells. *Journal of Biological Chemistry*, **2018**, 293, 17454-17463	5.4	11
187	Infection with flaviviruses requires BCLXL for cell survival. *PLoS Pathogens*, **2018**, 14, e1007299	7.6	18
186	IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. *Blood*, **2018**, 132, 2166-2178	2.2	42
185	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2017**, 23, 4527-4533	12.9	43
184	DR5 and caspase-8 are dispensable in ER stress-induced apoptosis. *Cell Death and Differentiation*, **2017**, 24, 944-950	12.7	51
183	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. *Blood*, **2017**, 129, 3362-3370	2.2	114
182	Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins. *Oncogene*, **2017**, 36, 4953-4962	9.2	8
181	Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. *Cell Death and Differentiation*, **2017**, 24, 878-888	12.7	62
180	NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression. *Nature Communications*, **2017**, 8, 928	17.4	46
179	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. *Science Translational Medicine*, **2017**, 9,	17.5	112
178	Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1298-1303	4.3	17

177	Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. *Clinical Pharmacology and Therapeutics*, **2017**, 101, 89-98	6.1	74
176	Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia. *Oncotarget*, **2017**, 8, 57948-57963	3.3	3
175	MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. *Cell Death and Disease*, **2016**, 7, e2345	9.8	42
174	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. *Blood*, **2016**, 128, 1382-95	2.2	100
173	Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis. *Nature Microbiology*, **2016**, 1, 15034	26.6	46
172	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. *Nature*, **2016**, 538, 477-482	30.4	617
171	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. *Leukemia*, **2016**, 30, 1531-41	10.7	22
170	Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy. *MedChemComm*, **2016**, 7, 778-787	5	11
169	HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. *Cell Death and Disease*, **2016**, 7, e2051	9.8	83
168	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. *Cell Reports*, **2016**, 14, 1858-66	10.6	25
167	Current challenges and novel treatment strategies in double hit lymphomas. *Therapeutic Advances in Hematology*, **2016**, 7, 52-64	5.7	19
166	Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax. *Blood*, **2016**, 128, 3223-3223	2.2	2
165	The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. *Oncotarget*, **2016**, 7, 2721-33	3.3	13
164	Targeting the Pro-Survival BCL2 Proteins with BH3 Mimetic Compounds for Treating Multiple Myeloma. *Blood*, **2016**, 128, 3293-3293	2.2	
163	The Role of BAX/BAK-Mediated Apoptosis for the Cytotoxic Action of Anti-Myeloma Agents. *Blood*, **2016**, 128, 5706-5706	2.2	
162	Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies. *Nature Communications*, **2016**, 7, 11734	17.4	37
161	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. *Blood*, **2016**, 127, 3215-24	2.2	181
160	Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. *Cell Death and Differentiation*, **2016**, 23, 2054-2062	12.7	18

159	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. *Blood*, **2016**, 128, 1834-1844	2.2	105
158	Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α production. *Arthritis and Rheumatology*, **2015**, 67, 797-808	9.5	35
157	Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. *Science Translational Medicine*, **2015**, 7, 279ra40	17.5	344
156	A transgenic mouse model to inducibly target prosurvival Bcl2 proteins with selective BH3 peptides in vivo. *Cell Death and Disease*, **2015**, 6, e1679	9.8	1
155	A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. *Nature Communications*, **2015**, 6, 6442	17.4	74
154	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. *Clinical Cancer Research*, **2015**, 21, 3216-29	12.9	47
153	Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes. *Diabetologia*, **2015**, 58, 140-8	10.3	24
152	A Chemical Screening Approach to Identify Novel Key Mediators of Erythroid Enucleation. *PLoS ONE*, **2015**, 10, e0142655	3.7	8
151	Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 4044-9	11.5	39
150	BCL2 inhibition in double hit lymphoma. *Leukemia and Lymphoma*, **2015**, 56, 1928-9	1.9	1
149	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. *Genes and Development*, **2014**, 28, 58-70	12.6	121
148	Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 8512-7	11.5	141
147	Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 261-6	11.5	41
146	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. *Leukemia*, **2014**, 28, 1207-15	10.7	69
145	Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition. *MedChemComm*, **2014**, 5, 1834-1842	5	21
144	Further insights into the effects of pre-organizing the BimBH3 helix. *ACS Chemical Biology*, **2014**, 9, 838-9	4.9	24
143	De-novo designed library of benzoylureas as inhibitors of BCL-XL: synthesis, structural and biochemical characterization. *Journal of Medicinal Chemistry*, **2014**, 57, 1323-43	8.3	31
142	Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. *ACS Medicinal Chemistry Letters* , **2014**, 5, 662-7	4.3	36

141	197. *Cytokine*, **2014**, 70, 75-76	4	
140	A biosensor of SRC family kinase conformation by exposable tetracysteine useful for cell-based screening. *ACS Chemical Biology*, **2014**, 9, 1426-31	4.9	9
139	Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. *Cell*, **2014**, 159, 1549-62	56.2	475
138	Simplified silvestrol analogues with potent cytotoxic activity. *ChemMedChem*, **2014**, 9, 1556-66	3.7	14
137	Targeting BCL2 for the treatment of lymphoid malignancies. *Seminars in Hematology*, **2014**, 51, 219-27	4	112
136	Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting. *Blood*, **2014**, 124, 988-988	2.2	2
135	ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.. *Journal of Clinical Oncology*, **2014**, 32, 7015-7015	2.2	33
134	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. *Blood*, **2013**, 122, 738-48	2.2	47
133	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nature Medicine*, **2013**, 19, 202-8	50.5	1922
132	Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II. *Organic Letters*, **2013**, 15, 1406-9	6.2	44
131	Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. *Cell*, **2013**, 152, 519-31	56.2	402
130	Structure-guided design of a selective BCL-X(L) inhibitor. *Nature Chemical Biology*, **2013**, 9, 390-7	11.7	277
129	Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL. *Journal of Medicinal Chemistry*, **2013**, 56, 5514-40	8.3	50
128	Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. *ACS Chemical Biology*, **2013**, 8, 297-302	4.9	109
127	BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 909-11	1.9	2
126	MCMV-mediated inhibition of the pro-apoptotic Bak protein is required for optimal in vivo replication. *PLoS Pathogens*, **2013**, 9, e1003192	7.6	17
125	Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 2599-604	11.5	37
124	Variability of inducible expression across the hematopoietic system of tetracycline transactivator transgenic mice. *PLoS ONE*, **2013**, 8, e54009	3.7	19

123	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. *Blood*, **2013**, 122, 1304-1304	2.2	8
122	Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. *Blood*, **2012**, 119, 4283-90	2.2	57
121	Synthesis and biological evaluation of a potent salicylihalamide A lactam analogue. *Organic and Biomolecular Chemistry*, **2012**, 10, 8147-53	3.9	11
120	The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. *Cell Death and Disease*, **2012**, 3, e443	9.8	41
119	A cluster of interferon-□nducible p65 GTPases plays a critical role in host defense against Toxoplasma gondii. *Immunity*, **2012**, 37, 302-13	32.3	230
118	The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. *Immunity*, **2012**, 36, 646-57	32.3	224
117	Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. *Blood*, **2012**, 119, 5807-16	2.2	150
116	Total synthesis of 2□5□diepisilvestrol and its C1□epimer: key structure activity relationships at C1□and C2□ *Journal of Natural Products*, **2012**, 75, 1500-4	4.9	17
115	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. *Journal of Clinical Oncology*, **2012**, 30, 488-96	2.2	622
114	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 2766-71	11.5	156
113	Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. *Clinical Cancer Research*, **2012**, 18, 783-95	12.9	92
112	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. *Cell Death and Disease*, **2012**, 3, e409	9.8	36
111	Sheeppox virus SPPV14 encodes a Bcl-2-like cell death inhibitor that counters a distinct set of mammalian proapoptotic proteins. *Journal of Virology*, **2012**, 86, 11501-11	6.6	32
110	Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity. *Journal of Medicinal Chemistry*, **2011**, 54, 1914-26	8.3	55
109	Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. *Blood*, **2011**, 118, 1663-74	2.2	199
108	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. *Pathology*, **2011**, 43, 525-35	1.6	33
107	Cyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein Bim. *EMBO Reports*, **2011**, 12, 77-83	6.5	49
106	Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. *Nature*, **2011**, 471, 110-4	50.4	602

105	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. *Journal of Experimental Medicine*, **2011**, 208, 2017-31	16.6	139
104	Deerpox virus encodes an inhibitor of apoptosis that regulates Bak and Bax. *Journal of Virology*, **2011**, 85, 1922-34	6.6	33
103	Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis. *Journal of Leukocyte Biology*, **2011**, 90, 819-29	6.5	11
102	Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma. *Immunology and Cell Biology*, **2011**, 89, 595-603	5	9
101	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. *Journal of Cell Biology*, **2011**, 194, i12-i12	7.3	
100	Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. *Nature*, **2010**, 463, 103-7	50.4	485
99	Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases. *Cell Death and Differentiation*, **2010**, 17, 821-32	12.7	29
98	Glucose induces pancreatic islet cell apoptosis that requires the BH3-only proteins Bim and Puma and multi-BH domain protein Bax. *Diabetes*, **2010**, 59, 644-52	0.9	90
97	BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 10967-71	11.5	88
96	The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics. *Journal of Immunology*, **2010**, 185, 2555-62	5.3	24
95	Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. *PLoS Pathogens*, **2010**, 6, e1001236	7.6	74
94	Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. *Cell Death and Disease*, **2010**, 1, e43	9.8	22
93	Transgenic, inducible RNAi in megakaryocytes and platelets in mice. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2751-6	15.4	10
92	Megakaryocytes Possess a Functional Intrinsic Apoptosis Pathway That Must Be Restrained In Order to Survive and Produce Platelets. *Blood*, **2010**, 116, 550-550	2.2	
91	Novel Bcl-2 homology-3 domain-like sequences identified from screening randomized peptide libraries for inhibitors of the pro-survival Bcl-2 proteins. *Journal of Biological Chemistry*, **2009**, 284, 31315-26	5.4	26
90	MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation. *Journal of Immunology*, **2009**, 183, 261-9	5.3	66
89	Correction for Fletcher et al., Inaugural Article: Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 1678-1678	11.5	78
88	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. *Leukemia*, **2009**, 23, 2034-41	10.7	84

87	XIAP discriminates between type I and type II FAS-induced apoptosis. *Nature*, **2009**, 460, 1035-9	50.4	344
86	Virally mediated inhibition of Bax in leukocytes promotes dissemination of murine cytomegalovirus. *Cell Death and Differentiation*, **2009**, 16, 312-20	12.7	32
85	Bax activation by Bim?. *Cell Death and Differentiation*, **2009**, 16, 1187-91	12.7	75
84	betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. *Molecular Cell*, **2009**, 33, 109-16	7.6	138
83	BH3-mimetics--the solution to chemoresistance?. *Leukemia and Lymphoma*, **2009**, 50, 1069-72	1.9	4
82	Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. *Blood*, **2009**, 114, 663-6	2.2	240
81	BH3-only proteins and their roles in programmed cell death. *Oncogene*, **2008**, 27 Suppl 1, S128-36	9.2	153
80	Controlling the cell death mediators Bax and Bak: puzzles and conundrums. *Cell Cycle*, **2008**, 7, 39-44	4.7	52
79	A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. *Journal of Cell Biology*, **2008**, 180, 341-55	7.3	146
78	Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 18081-7	11.5	141
77	Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic beta-cells. *Diabetes*, **2008**, 57, 1284-92	0.9	78
76	Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. *Cell Death and Differentiation*, **2008**, 15, 1564-71	12.7	177
75	EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency. *Cell Death and Differentiation*, **2008**, 15, 1609-18	12.7	10
74	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17961-6	11.5	124
73	(alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. *Journal of the American Chemical Society*, **2007**, 129, 139-54	16.4	156
72	Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. *Nature Immunology*, **2007**, 8, 856-63	19.1	196
71	Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. *Cell Death and Differentiation*, **2007**, 14, 128-36	12.7	179
70	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. *PLoS Medicine*, **2007**, 4, 1681-89; discussion 1690	11.6	261

69	Structural insights into the degradation of Mcl-1 induced by BH3 domains. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 6217-22	11.5	364
68	Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. *Journal of Cell Biology*, **2007**, 177, 277-87	7.3	102
67	Programmed anuclear cell death delimits platelet life span. *Cell*, **2007**, 128, 1173-86	56.2	763
66	The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. *Cell*, **2007**, 129, 423-33	56.2	170
65	Response: Does Bid Play a Role in the DNA Damage Response?. *Cell*, **2007**, 130, 10-11	56.2	10
64	A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. *Molecular Cell*, **2007**, 25, 933-42	17.6	110
63	Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. *Science*, **2007**, 315, 856-9	33.3	937
62	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. *Cancer Cell*, **2006**, 10, 389-99	24.3	1049
61	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 14907-12	11.5	291
60	Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. *Cell Death and Differentiation*, **2006**, 13, 109-18	12.7	57
59	CED-4 forms a 2 : 2 heterotetrameric complex with CED-9 until specifically displaced by EGL-1 or CED-13. *Cell Death and Differentiation*, **2006**, 13, 426-34	12.7	21
58	BH3-only proteins: orchestrating cell death. *Cell Death and Differentiation*, **2006**, 13, 1268-71	12.7	18
57	How the Bcl-2 family of proteins interact to regulate apoptosis. *Cell Research*, **2006**, 16, 203-13	24.7	266
56	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. *Genes and Development*, **2005**, 19, 1294-305	12.6	981
55	Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. *Molecular Cell*, **2005**, 17, 393-403	17.6	1492
54	FADD and caspase-8 are required for cytokine-induced proliferation of hemopoietic progenitor cells. *Blood*, **2005**, 106, 1581-9	2.2	51
53	Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 16182-7	11.5	129
52	Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. *Journal of Biological Chemistry*, **2005**, 280, 4738-44	5.4	162

51	Subversion of the Bcl-2 life/death switch in cancer development and therapy. *Cold Spring Harbor Symposia on Quantitative Biology*, **2005**, 70, 469-77	3.9	21
50	Modifications and intracellular trafficking of FADD/MORT1 and caspase-8 after stimulation of T lymphocytes. *Cell Death and Differentiation*, **2004**, 11, 724-36	12.7	42
49	Nuclear localisation of FADD rebuttal. *Cell Death and Differentiation*, **2004**, 11, 1362-1363	12.7	4
48	Protein hijacking: key proteins held captive against their will. *Cancer Cell*, **2004**, 5, 107-8	24.3	9
47	Localization of dynein light chains 1 and 2 and their pro-apoptotic ligands. *Biochemical Journal*, **2004**, 377, 597-605	3.8	63
46	The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. *EMBO Journal*, **2003**, 22, 1497-507	13	138
45	Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. *Cell Death and Differentiation*, **2003**, 10, 185-92	12.7	37
44	The Bcl-2 family: roles in cell survival and oncogenesis. *Oncogene*, **2003**, 22, 8590-607	9.2	1232
43	Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. *Journal of Cell Biology*, **2003**, 162, 877-87	7.3	99
42	The Bcl-2-regulated apoptotic pathway. *Journal of Cell Science*, **2003**, 116, 4053-6	5.3	166
41	Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. *Biochemical Pharmacology*, **2002**, 64, 851-63	6	121
40	Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. *Cell Death and Differentiation*, **2002**, 9, 832-41	12.7	156
39	Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. *Nature*, **2002**, 419, 634-7	50.4	463
38	Direct addition of BimL to mitochondria does not lead to cytochrome c release. *FEBS Letters*, **2002**, 522, 29-34	3.8	35
37	Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. *Mammalian Genome*, **2001**, 12, 163-8	3.2	124
36	Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. *Cell Death and Differentiation*, **2001**, 8, 486-94	12.7	83
35	Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. *Science*, **2001**, 293, 1829-32	33.3	505
34	Rapid selection against truncation mutants in yeast reverse two-hybrid screens. *BioTechniques*, **2001**, 30, 984-8	2.5	11

33	The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control. *Annals of the New York Academy of Sciences*, **2000**, 917, 541-8	6.5	100
32	The role of the pro-apoptotic Bcl-2 family member bim in physiological cell death. *Annals of the New York Academy of Sciences*, **2000**, 926, 83-9	6.5	24
31	Bcl-2 does not inhibit cell death induced by the physiological Fas ligand: implications for the existence of type I and type II cells. *Cell Death and Differentiation*, **2000**, 7, 754-5	12.7	32
30	Apoptosis and cell division. *Current Opinion in Cell Biology*, **2000**, 12, 257-63	9	58
29	Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD. *Journal of Immunology*, **2000**, 165, 1337-43	5.3	56
28	Pro-apoptotic apoptosis protease-activating factor 1 (Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-x(L). *Journal of Cell Biology*, **2000**, 149, 623-34	7.3	125
27	Transgenic overexpression of human Bcl-2 in islet beta cells inhibits apoptosis but does not prevent autoimmune destruction. *International Immunology*, **2000**, 12, 9-17	4.9	55
26	Debcl, a proapoptotic Bcl-2 homologue, is a component of the Drosophila melanogaster cell death machinery. *Journal of Cell Biology*, **2000**, 148, 703-14	7.3	149
25	The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. *American Journal of Pathology*, **2000**, 157, 449-61	5.8	201
24	BH3-Only proteins-essential initiators of apoptotic cell death. *Cell*, **2000**, 103, 839-42	56.2	899
23	Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 9683-8	11.5	134
22	Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 14871-6	11.5	276
21	Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. *Cell Death and Differentiation*, **1999**, 6, 525-32	12.7	44
20	Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. *EMBO Journal*, **1999**, 18, 3034-43	13	226
19	Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. *Science*, **1999**, 286, 1735-8	33.3	1288
18	The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. *Molecular Cell*, **1999**, 3, 287-96	17.6	911
17	Control of apoptosis in hematopoietic cells by the Bcl-2 family of proteins. *Cold Spring Harbor Symposia on Quantitative Biology*, **1999**, 64, 351-8	3.9	25
16	Bim: a novel member of the Bcl-2 family that promotes apoptosis. *EMBO Journal*, **1998**, 17, 384-95	13	893

15	The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. *EMBO Journal*, **1998**, 17, 1029-39	13	177
14	Rapid hybridoma screening method for the identification of monoclonal antibodies to low-abundance cytoplasmic proteins. *BioTechniques*, **1998**, 25, 824-30	2.5	39
13	Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. *Oncogene*, **1997**, 14, 405-14	9.2	231
12	The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1997**, 1333, F151-78	11.2	62
11	The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. *EMBO Journal*, **1997**, 16, 4628-38	13	255
10	The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.. *EMBO Journal*, **1996**, 15, 6979-6990	13	268
9	The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. *EMBO Journal* , **1996**, 15, 6979-90	13	112
8	bcl-w, a novel member of the bcl-2 family, promotes cell survival. *Oncogene*, **1996**, 13, 665-75	9.2	217
7	Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis.. *EMBO Journal*, **1995**, 14, 6136-6147	13	525
6	Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. *EMBO Journal*, **1995**, 14, 6136-47	13	203
5	Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. *Molecular and Cellular Biology*, **1993**, 13, 2420-31	4.8	70
4	Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. *Molecular and Cellular Biology*, **1993**, 13, 2420-2431	4.8	32
3	Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. *British Journal of Haematology*, **1992**, 81, 231-4	4.5	9
2	BAX requires VDAC2 to mediate apoptosis and to limit tumor development		1
1	Comprehensive characterization of single cell full-length isoforms in human and mouse with long-read sequencing		10